First 24-Hour Painkiller Available Soon To 3.2 Million Australians
This article was originally published in PharmAsia News
Executive Summary
Australians soon will have access to their first 24-hour painkiller under the country's Pharmaceutical Benefits Scheme. The government has approved coverage of Durotram XR (tramadol) made by Ortho McNeil Janssen. Pain specialists cheered the inclusion of the drug as one way to reduce dependence on morphine and oxycodone, both of which can lead to misuse. Chronic pain in Australia is estimated to affect about 3.2 million people. (Click here for more
You may also be interested in...
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.